Good-first: B/F/TAF As First-line ART

Recruiting now

Conditions studied: HIV Infection

In brief

This is a multicohort study conducted at Affiliated Hospital of Nantong University, and Nantong Third Peoples Hospital (Designated Hospital for HIV/AIDS Treatment of Nantong City), China. The study would involve 630 patients initiating HIV treatment, divided into six cohorts. The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.

Key facts

Study ID

NCT06619288

Run by

Affiliated Hospital of Nantong University

People needed

630

Starts

2024-07-01

Expected to finish

2026-06-30

Last updated by the study team

2024-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years) diagnosed with HIV/AIDS, ART-naive, from July 2024 to June 2025 (prospective) or January 2020 to June 2023 (retrospective).
• Eligible for ART initiation with B/F/TAF or previously treated with TDF+3TC+EFV or DTG/3TC.
• Willing to adhere to study procedures and follow-up visits or have complete electronic health records (EHRs).

You may not qualify if…

• Severe renal impairment (creatinine clearance \< 50 mL/min).
• Hepatitis B co-infection or severe hepatic impairment (Child-Pugh Class C).
• Active tuberculosis (TB).

Where it is running

• Nantong Third Peoples Hospital — Nantong, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.